UK govt tears up price deal with drug industry

10 March 2008

The UK's Department of Health has issued a six-month notice of termination for the Pharmaceutical Price Regulation System, effective September 1. A spokesperson for the DoH said: "the Department of Health and the Association of the British Pharmaceutical Industry wish to clarify that, while negotiations on a potential new PPRS agreement have begun, neither party is commenting on any speculation on the content of these negotiations."

Both sides agree on basis for new deal

She added that "the government considers that six months' notice has to be given as part of these negotiations and moving towards a new agreement. The parties have agreed that the Government's four principles in response to the 2007 Office of Fair Trading report will be the basis of any new agreement." These are: value for money; reward for innovation; accelerated uptake of new medicines; and sustainability. The government insisted that "both sides are seeking to agree a new voluntary PPRS."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight